Profile data is unavailable for this security.
About the company
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
- Revenue in USD (TTM)177.60m
- Net income in USD-4.89m
- Incorporated2002
- Employees203.00
- LocationVanda Pharmaceuticals IncSUITE 300E, 2200 PENNSYLVANIA AVE NWWASHINGTON 20037United StatesUSA
- Phone+1 (202) 734-3400
- Fax+1 (202) 296-1450
- Websitehttps://www.vandapharma.com/
More ▼
Mergers & acquisitions
| Acquired company | VNDA:NMQ since announced | Transaction value |
|---|---|---|
| Actelion Pharmaceuticals Ltd-PONVORY | 35.64% | 100.00m |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procaps Group SA | 414.10m | 52.20m | 300.11m | 5.50k | 5.11 | 7.62 | 4.31 | 0.7247 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Caribou Biosciences Inc | 33.40m | -115.26m | 306.18m | 158.00 | -- | 0.8919 | -- | 9.17 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 307.41m | 75.00 | -- | 0.5485 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Poseida Therapeutics Inc | 82.50m | -108.86m | 309.29m | 335.00 | -- | 3.65 | -- | 3.75 | -1.18 | -1.18 | 0.8907 | 0.8739 | 0.2864 | -- | 8.06 | 250,006.10 | -37.78 | -40.70 | -49.17 | -47.72 | -- | -- | -131.94 | -233.49 | -- | -12.88 | 0.4096 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 310.93m | 122.00 | -- | 2.97 | -- | 433.61 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 315.43m | 534.00 | -- | -- | -- | 1.33 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| AC Immune SA | 16.28m | -59.67m | 315.45m | 133.00 | -- | 1.78 | -- | 19.37 | -0.7061 | -0.7061 | 0.1918 | 1.78 | 0.0803 | -- | 1.92 | 122,440.00 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Vanda Pharmaceuticals Inc. | 177.60m | -4.89m | 318.93m | 203.00 | -- | 0.5863 | -- | 1.80 | -0.0846 | -0.0846 | 3.08 | 9.35 | 0.2738 | 10.32 | 5.80 | 874,896.60 | -0.7538 | 6.61 | -0.8808 | 7.62 | 92.42 | 90.55 | -2.75 | 15.18 | 4.69 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 322.26m | 137.00 | -- | 2.54 | -- | 3.57 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Sutro Biopharma Inc | 154.07m | -114.96m | 328.00m | 300.00 | -- | 2.55 | -- | 2.13 | -1.89 | -1.89 | 2.53 | 1.57 | 0.4047 | -- | 7.48 | 510,149.00 | -30.20 | -25.48 | -36.94 | -29.75 | -- | -- | -74.62 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Ventyx Biosciences Inc | 0.00 | -192.60m | 333.46m | 74.00 | -- | 1.09 | -- | -- | -3.24 | -3.24 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -53.41 | -- | -55.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 334.05m | 123.00 | -- | 11.94 | -- | 8.72 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Alto Neuroscience Inc | 0.00 | -42.44m | 335.24m | 67.00 | -- | 1.74 | -- | -- | -1.90 | -1.90 | 0.00 | 7.18 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.049 | -- | -- | -- | -31.02 | -- | -- | -- |
| Fractyl Health Inc | 148.00k | -83.16m | 338.02m | 102.00 | -- | 4.02 | -- | 2,283.92 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
| Skye Bioscience Inc | 0.00 | -37.50m | 338.16m | 11.00 | -- | 4.29 | -- | -- | -4.50 | -4.50 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -75.43 | -232.67 | -101.00 | -- | -- | -- | -- | -- | -- | -46.11 | 0.0552 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
Data as of May 17 2024. Currency figures normalised to Vanda Pharmaceuticals Inc's reporting currency: US Dollar USD
42.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.39m | 9.38% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 3.68m | 6.40% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.31m | 5.75% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 2.37m | 4.12% |
| D. E. Shaw & Co. LPas of 31 Dec 2023 | 2.11m | 3.67% |
| Pictet Asset Management SAas of 31 Dec 2023 | 1.92m | 3.34% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 1.72m | 2.99% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.47m | 2.55% |
| Jacobs Levy Equity Management, Inc.as of 31 Dec 2023 | 1.43m | 2.49% |
| PGIM Quantitative Solutions LLCas of 31 Dec 2023 | 1.31m | 2.27% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
